Expression of the homeobox gene Xanf-1 starts within the presumptive forebrain primordium of the Xenopus embryo at the midgastrula stage and is inhibited by the late neurula. Such stage-specific inhibition is essential for the normal development as the experimental prolongation of the Xanf-1 expression elicits severe brain abnormalities. To identify transcriptional regulators that are responsible for the Xanf-1 inhibition, we have used the yeast one-hybrid system and identified a novel Xenopus homeobox gene X-nkx-5.1 that belongs to a family of Nkx-5.1 transcription factors. In terms of gene expression, X-nkx-5.1 shares many common features with its orthologs in other species, including expression in the embryonic brain and in the ciliated cells of the otic and lateral line placodes. However, we have also observed several features specific for X-nkx-5.1, such as expression in precursors of the epidermal ciliated cells that may indicate a possible common evolutionary origin of all ciliated cells derived from the embryonic ectoderm. Another specific feature is that the X-nkx-5.1 expression in the anterior neural plate starts early, within the area overlapping the Xanf-1 expression territory at the midneurula stage, and it correlates with the beginning of the Xanf-1 inhibition. Using various loss and gain-of-function techniques, including microinjections of antisense morpholino oligonucleotides and mRNA encoding for the X-nkx-5.1 and its dominant repressor and activator versions, we have shown that X-nkx-5.1 can indeed play a role of stage-specific inhibitor of Xanf-1 in the anterior neural plate during the Xenopus development.
Introduction
One of the earliest events in the process of the neural plate patterning is determination of the anterior-most domain corresponding to the prospective forebrain. It is demarcated by expression of the homeobox gene Anf/Hesx1/Rpx (Zaraisky et al., 1992; Thomas et al., 1995; Hermesz et al., 1996; Kazanskaya et al., 1997) . As neurulation proceeds, the Anf expression within the neural plate is progressively reduced, from posterior towards anterior, being entirely inhibited by the end of this stage (Kazanskaya et al., 1997) . However, in the presumptive pituitary cells derived from the medial sector of the anterior neural ridge, the Anf expression persists until the tailbud stage in Xenopus, and 15.5 stage in mouse (Kazanskaya et al., 1997) .
The crucial role of Anf for the forebrain development is demonstrated by analysis of mutations in human and mouse Anf, Hesx1/Rpx, that elicit severe disorder, septo-optic dysplasia (Dattani et al., 1998) . Previously, we have shown that the timely inhibition of the Anf expression in the cells of the anterior neurectoderm is essential for the normal patterning of this region. Experimental prolongation of expression of the Xenopus Anf, Xanf-1, in the anterior neurectoderm perturbs the expression of at least several forebrain regulators, including Bf-1, Otx-2 and Pax-6 (Ermakova et al., 1999) . This perturbation results in size reduction of the forebrain, eyes and nasal placodes.
In mammals, the timely inhibition of the expression of mammalian Xanf-1 counterpart, Rpx/Hesx1, is also suggested to be essential for the normal pituitary development (Scully and Rosenfeld, 2002) .
Recently, we have identified a 34-bp fragment of the Xanf-1 promoter, which is crucial for maintenance of the correct expression pattern at the neural anlage and contains multiple putative transcription factor binding sites (Eroshkin et al., 2002) . We have used this fragment as a target for the yeast one-hybrid screening of the Xenopus neurula cDNA expression library to identify genes of transcription factors that may bind the Xanf-1 promoter. One of the identified genes encodes for a novel Xenopus ortholog of the mammalian homeodomain protein nkx-5.1. Our data show that the expression of this gene overlaps with the Xanf-1 expression domain in the anterior neural fold, and correlates with the beginning of the Xanf-1 inhibition. Accordingly, we have proposed that X-nkx-5.1 may be responsible for the observed Xanf-1 inhibition during neurulation. To analyze the role of X-nkx-5.1, we have used various loss-and gain-of-function techniques, including microinjections into the embryos of the antisense morpholino oligonucleotides and mRNAs encoding for the dominant repressor and activator versions of this transcription regulator. Our data show that X-nkx-5.1 could indeed play a role of a direct repressor of Xanf-1 in the anterior neurectoderm.
Results

Identification of transcription factors binding to the Xanf-1 promoter using the yeast one-hybrid system
Previously, we have identified the 34-bp element of the Xanf-1 promoter, which is crucial for maintaining the expression of this gene at the proper levels and specific locations within the anterior neurectoderm (Eroshkin et al., 2002) . This element contains putative binding sites for several types of transcription factors. However, direct testing of these factors in the Xenopus embryos by microinjections could be excessively time-consuming due to our limited knowledge on transcriptional regulation in the developing neural plate. Therefore we have used the yeast one-hybrid system to identify genes encoding transcription factors that are able to bind to the 34-bp Xanf-1 promoter element. Both the one-hybrid system and a cDNA library of the late gastrula of Xenopus laevis were commercially obtained from the Clontech Laboratories, however, they were incompatible, because the library was prepared in the two-hybrid system cloning vector, Lex-A. In a preliminary work, we performed mating of the one-hybrid system yeast strain containing an integrated reporter plasmid with the 34-bp Xanf-1 promoter element, with the yeast strain from Lex-A two-hybrid system. The obtained diploid yeast strain became suitable for the one-hybrid system and it was transformed with the Xenopus gastrula cDNA library. Approximately 100 yeast colonies were selected for activation of the b-gal reporter gene (blue color on the appropriate selective medium as described in the Materials and Methods), and tested by re-transformation into the yeast strain containing the Xanf-1 promoter target. In total, 8 unique clones containing cDNA of the following transcription factors were identified, including Dlx-2, Dlx-5, HOXB9, Msx-1, X-nkx-5.1, Pintallavis, Xvent-1 and Xvent-2.
These factors were tested using in situ hybridization of the whole-mount embryos at the neurula stage. For 7 of the 8 identified factors, the expression domains have been localized either in the regions of ectoderm not directly contacting with the Xanf-1 expression domain (Dlx-2, HOXB9, Xvent-1), or in the areas abutting it from the anterior (Dlx-5), lateral (Msx-1) or posterior sides (Pintallavisand Xvent-2). Therefore, these factors could not be responsible for the observed inhibition of the Xanf-1 expression within its normal expression domain towards the end of neurulation. However, some of these factors could play a role of Xanf-1 suppressors in other regions of the Xenopus embryo, and we have recently demonstrated that Pintallavis and Xvent-2 are essential for determination of the posterior limit of the Xanf-1 expression area (Martynova et al., 2004) . Thus, only one of the 8 identified transcription factors, X-nkx-5.1 could be involved in transcriptional control of the Xanf-1 gene expression within its normal expression domain. The expression of X-nkx-5.1 starts in the neural plate within the area that overlaps with the Xanf-1 expression domain at the midneurula stage and it correlates with the beginning of the Xanf-1 inhibition.
Cloning of the X-nkx-5.1 full-length cDNA
Screening of the yeast library provided only a fragment of the X-nkx-5.1 cDNA containing the 3 0 -end and the homeodomain. We have used the PCR-based RACE technology (Kazanskaya et al., 1997) to clone an additional fragment containing the 5 0 non-coding region and 5 0 -end. Then, the full-length open reading frame has been cloned by RT-PCR based on sequence information from the cloned cDNA fragments. In total, 5 independent clones were used to accurately determine the sequence of the full-length cDNA (AF368235).
A BLAST database search has confirmed that the X-nkx-5.1 protein has a high similarity to the previously cloned Nkx-5.1 proteins from other animals ( Fig. 1) , especially in the homeodomains that are 100% identical between the Xenopus protein and the ones from zebrafish, medaka, chick and mouse (Fig. 1) . In contrast, comparison of the X-nkx-5.1 homeodomain with the homeodomains of nkx proteins of other sub-families, in particular Nkx-5.2, shows a much smaller similarity (data not shown). Outside of the homeodomain, the similarity of X-nkx-5.1 with other known nkx-5.1 proteins is lower, except for several short motifs near the N-and C-termini. One of these motifs (Fig. 1 , red dotted line) has been previously suggested to be responsible for the repression function of the mouse ortholog of X-nkx-5.1 through its binding with the Groucho corepressor (Smith and Jaynes, 1996) .
Expression pattern of X-nkx-5.1
The temporal expression pattern of X-nkx-5.1 has been analysed by the RT-PCR assay. The expression begins at the early gastrula, gradually increases by the mid-late neurula stages, and then persists at the level achieved during neurulation ( Fig. 2A) .
To investigate the spatial pattern of the X-nkx-5.1 expression, we have performed in situ hybridisation in the whole mount embryos. The expression reaches the level of detection at the beginning of gastrulation in single scattered cells of the animal hemisphere (Fig. 2B) . As gastrulation proceeds, the expression becomes stronger in the presumptive epidermal cells of the ventral and lateral regions of embryo ( Fig. 2C) but not in the dorsal side (Fig. 2D) . The hybridisation signal intensity in the scattered epidermal cells reaches its maximum at the stage 15 ( Fig. 2E and F) . Dissection of embryos at this stage shows that the X-nkx-5.1 expressing cells are located exclusively in the internal layer Fig. 1 . Comparison of the amino acid sequence of X. laevis Nkx-5.1 with its homologs from zebrafish (D.rerio),chick (G.gallus),mouse (M.musculus) and two homologs from medaka (O.latipes). Homeodomains are outlined by the black frame. The red dotted line indicates the motif suggested previously as a domain responsible for repression function of mouse Nkx-5.1 (Smith and Jaynes, 1996) . of the ectoderm (Fig. 2G) . Later the X-nkx-5.1 expression in these cells gradually decreases down to the background level by the tailbud stage (data not shown).
Within the neural plate, the X-nkx-5.1 expression begins at the midneurula stage, forming a diffuse domain entirely covering the anterior neural fold (Fig. 2J ). This X-nkx-1 expression domain in the anterior neurectoderm expands farther laterally than the expression territory of Xanf-1 (compare Fig. 2J and N) . Notably, the beginning of the X-nkx-5.1 expression in the anterior neural fold area coincides with the decline of the Xanf-1 expression in the same area (compare Fig. 2I -L with M-P). In contrast to X-nkx-5.1, the expression of Xanf-1 reaches its maximum at the end of gastrulation and gradually decreases during neurulation, persisting by the end of neurulation only outside the anterior margin of the neural plate, in the presumptive pituitary cells ( Fig. 2O and P, arrows) . This negative correlation between the Xanf-1 and X-nkx-5.1 expression in the anterior neural fold supports the hypothesis about a possible repressor role of X-nkx-5.1 in the Xanf-1 regulation.
As neurulation proceeds, the diffuse expression of X-nkx-5.1 in the head region of embryo expands posteriorly ( Fig. 2H and K) , and after the neural fold closing, it is detected on the dorsal side of the brain primordium, including the eye vesicles (Fig. 2L , Q and R). Interestingly, at the early tailbud stage, a weak X-nkx-5.1 expression becomes visible also in cells of the differentiating cement gland (Fig. 2R,  arrowhead) , and in the otic ganglion (Fig. 2R, arrow) .
At the late tailbud stage (stage 25-26) the X-nkx-5.1 expression increases sharply in several local domains within the neural tube. First, the two expression domains appear in the brain primordium: one in the prospective ventral forebrain (Fig. 2T , black arrowhead) and the other in the ventral mesencephalon (Fig. 2T , U, black arrows). Second, the longitudinal row of scattered cells expressing X-nkx-5.1 is detected on both side of the spinal cord (Fig. 2S, arrow) . Later, by the tadpole stage, the expression is localised within the ventral forebrain, in the two domains corresponding to the lamina terminalis (Fig. 2V , W, black arrowheads) and the ventral thalamus (Fig. 2V , W, red arrowheads). An additional domain of relatively weak expression is observed in the ventral part of the rostral hindbrain (Fig. 2V , W, red arrows). In addition, at this stage X-nkx-5.1 is expressed in scattered cells within the dorsal and lateral sides of the posterior hindbrain and in the spinal cord (Fig. 2V, W, black  arrows) .
Outside of the neural tube, the X-nkx-5.1 expression is observed starting from the tailbud stage in the anterior part of the otic vesicles (Fig. 2T ,U, green arrows), in the otic ganglion (Fig. 2T ,U, yellow arrows), and in the areas corresponding to middle (Fig. 2T ,U, red arrows) and anterioventral (Fig. 2T , red arrowhead) lateral line placodes.
2.4. Electrophoretic mobility shift assay confirms the X-nkx-5.1 binding to the Xanf-1 promoter regulatory element Electrophoretic mobility shift assay (EMSA) was used for an additional confirmation that X-nkx-5.1 could bind the 34-bp Xanf-1 promoter element used as a target in the yeast screen. Previously we have shown different functions in regulation of the Xanf-1 transcription for distal, 14-bp, and proximal, 22-bp, parts of the element (Eroshkin et al., 2002) . In the present work, we have performed EMSA separately with each of these parts ( Fig. 3 lanes 1-3 and 4-6 , respectively). Our data show that a crude extract of Xenopus oocytes microinjected with mRNAs of X-nkx-5.1 causes a very pronounced mobility shift for the 22-bp element (Fig. 3  lane 6) , and a much weaker mobility shift for the 14-bp element ( Fig. 3 lane 3) . The specificity of binding is confirmed by (i) the absence of mobility shift for the extract from oocytes microinjected with the EGFPmRNA (Fig. 3 (T,U) At the tailbud stage, the X-nkx-5.1 expression increases in two domains of the neural tube: one in the prospective forebrain (see the arrowhead) and the other in the ventral mesencephalon (the black arrow). It also sharply increases in the anterior part of otic vesicle (the green arrows), in otic ganglion (the yellow arrows) and in the areas, corresponding to the middle (the red arrows) and anterioventral (the red arrowhead) lateral line placodes. (V,W) At the tadpole stage, the X-nkx-5.1 expression is localized in the ventral forebrain in two domains corresponding to the lamina terminalis (the black arrowheads) and ventral thalamus (the red arrowheads), respectively. The comparatively weak expression is seen in the ventral part of the rostral hindbrain (the red arrows) and in scattered cells within the dorsal and lateral sides of posterior hindbrain and spinal cord (the black arrows). Fig. 3 . Electrophoretic mobility shift assays (EMSA) of the X-nkx-5.1 binding to the elements derived from the Xanf-1 promoter, including the 14 and 22 bp intact, and the 22 bp mutant ones. (A) Extracts from oocytes microinjected with mRNA encoding X-nkx-5.1 or EGFP (control) were incubated with the endlabeled elements from the Xanf-1 promoter and electrophoresed in a nondenaturing polyacrylamide gel. The reaction mixtures were the following: lanes 1, 4, 7, extracts from oocytes microinjected with EGFP mRNA (control) mixed with 14, 22 or 22 bp mutant elements, respectively; lanes 2, 5, 8, extracts from oocytes microinjected with the X-nkx-5.1 mRNA diluted ten times with the extract from oocytes microinjected with EGFP mRNA mixed with 14, 22 or 22 bp mutant elements, respectively; lanes 3, 6, 9, extracts from oocytes microinjected with X-nkx-5.1 mRNA mixed with 14, 22 or 22 bp mutant element respectively. (B) Alignment of the 22 bp element from the Xanf-1 promoter with the corresponding sequences from the chicken and human Anf genes demonstrates a high evolutionarily conservation of this element. The putative binding site of X-nkx-5.1 is outlined by the yellow box (see the text for details). lane 4), and (ii) a sharp reduction of the mobility shift that is observed if the extract from the X-nkx-5.1 microinjected oocytes was diluted 10 times with that from the EGFP microinjected oocytes (Fig. 3 lane 5) .
The weak X-nkx-5.1 binding to the 14-bp Xanf-1 promoter element ( Fig. 3 lane 3) may be caused by the common core site of many homeodomains, TAAT, which is present in this element. On the other hand, the strong X-nkx-5.1 binding to the 22-bp Xanf-1 promoter element ( Fig. 3 lane 6 ) may be caused by a specific motif, CAATTAACTC, similar to the optimal core binding site determined by the in vitro selection technique for mouse Nkx-5.1, CA(A/C)TTAA(G/T)TG (Mennerich et al., 1999) . The analysis performed in mice has shown that mutations of the nucleotides flanking the TTAA core only at one side result in a moderate reduction of the Nkx-5.1 binding ability. The Xanf-1 promoter sequence, CAATTAACTC, differs from the Nkx-5.1 consensus site in two positions, -1 and -3, flanking TTAA core just from one side. This finding is consistent with the observed ability of X-nkx-5.1 to bind the 22-bp Xanf-1 promoter element. In contrast, it is shown in mice that mutations of the conserved TTAA core of the Nkx-5.1 consensus site abolish Nkx-5.1 binding completely (Mennerich et al., 1999) . Therefore, to further confirm the specificity of binding of X-nkx-5.1 to the putative site in the 22-bp element from the Xanf-1 promoter, we have introduced a point mutation in positionC1 of TTAA core, changing the sequence to CAAGTAACTC. This mutation causes a dramatic reduction in the mobility shift ( Fig. 3C lane 9 ).
X-nkx-5.1 can inhibit expression of Xanf-1 in living embryos
To understand the role of X-nkx-5.1 in the regulation of Xanf-1 expression, we have microinjected mRNAs encoding for normal protein (X-nkx-5.1), dominant activator (VP16-X-nkx-5.1) and dominant repressor (EnR-X-nkx-5.1) versions of this factor into the embryos. In all cases, the microinjected mRNA was mixed with the fluorescent tracer, Fluorescein-Lysine-Dextran (FLD), which allowed us to track the progenies of the microinjected blastomeres. Our results show that overexpression of both normal and repressor version in the neuroectoderm elicits a severe down-regulation of the endogenous Xanf-1 expression (Fig. 4A-C 0 , arrows). This effect is regularly observed in all embryos in which polyclones of the microinjected cells (labeled by FLD) crossed the area of normal expression of the endogenous Xanf-1 (25 and 21 embryos in total in two independent experiments for X-nkx-5.1 and EnR-X-nkx-5.1 mRNA, respectively). In contrast, the ectopic expression of the dominant activator VP16-X-nkx-5.1 results in an expansion of the Xanf-1 expression domain (Fig. 4D,D 0 , arrow). Interestingly, in all the cases (24 embryos in total in two experiments), the expansion occurred exclusively in the anterior or lateral directions but never in the posterior one.
These data indicate that X-nkx-5.1 is the transcriptional repressor of Xanf-1, thus, the ectopic expression of the dominant activator fusion of X-nkx-5.1 should elicit anatomical abnormalities similar to those observed for the ectopic expression of Xanf-1 (Ermakova et al., 1999) . And indeed, this is true for the embryos microinjected with the VP16-X-nkx-5.1 mRNA and traced until the tailbud and tadpole stages. First, we have observed the formation of secondary axes (19 embryos in 2 independent experiments) when the VP16-X-nkx-5.1 mRNA has been microinjected into the ventral blastomeres (Fig. 4E, arrowhead) . Notably, all secondary axes contained only the trunk part of the normal body axis, extending from the tail till the level of otic vesicles. The same partial secondary axes have been observed previously when Xanf-1 has been ectopically expressed in descendants of the ventral blastomeres, this effect simulates the normal role of Xanf-1 during the development of the Spemann organizer (Zaraisky et al., 1995) . Second, we have observed suppression, or splitting of the cement gland. This malformation is regularly observed (10 embryos in 2 independent experiments) when a clone of cells bearing VP16-X-nkx-5.1 mRNA crosses the cement gland area (Fig. 4F ,G, arrowheads). As shown previously for the Xanf-1 mRNA microinjections, such abnormality is caused by inhibition of the cement gland differentiation with the ectopic Xanf-1 (Ermakova et al., 1999) . Third, abnormal brain outgrowths or bulges have been developed if descendants of the microinjected blastomeres intensively populated the anterior ectoderm (evaluated in 15 embryos in 2 independent experiments) ( Fig. 4H-J, arrows) . In the case of Xanf-1 mRNA microinjections, this abnormality is due to the ability of Xanf-1 to neuralise prospective epidermis near the neural plate (Ermakova et al., 1999) . Interestingly, in different embryos such brain outgrowths could be located at different positions along the anterior-posterior axis but always anterior to the hind-midbrain boundary. This observation is consistent with the described ability of the VP16-X-nkx-5.1 to expand Xanf-1 expression domain only in the anterior and lateral but not posterior directions. Finally, a partial or entire reduction of eyes has been regularly observed on the side of embryo populated by the microinjected cells (21 embryos in 2 independent experiments) ( Fig. 4I,J) . Frequently (12 embryos in total), the remaining part of the eye has been jointed directly to the enlarged forebrain. This may indicate conversion of a part of the presumptive eye tissue into the forebrain. This effect is consistent with the ability of ectopic Xanf-1 to suppress the expression of one of the eye's master gene Pax-6, and, as a consequence, to inhibit eye development (Ermakova et al., 1999) . Accordingly, the observed malformation might be a result of inhibition of Pax-6 by the endogenous Xanf-1 expression which is activated by the microinjected VP16-Xnkx-5.1.
In contrast to VP16-X-nkx-5.1, microinjections of the EnR-X-nkx-5.1 mRNA elicit partial reduction of the forebrain (Fig. 4M, arrow) and do not cause formation of the secondary axis. At the same time, they also result in inhibition of the cement gland and eyes (Fig. 4M,  arrowhead) .
Similar effects, including the suppression of eye (Fig. 4N, arrowhead) and cement gland differentiation have been observed with microinjections of the normal X-nkx-5.1 mRNA. Similarly to EnR-X-nkx-5.1, this mRNA is also unable to induce the secondary axis formation. However, it elicits the development of the abnormal brain outgrowths (Fig. 4N, arrow) in the same way as the VP16-Xnkx-5.1 mRNA does. Assuming that X-nkx-5.1 and its dominant repressor version, EnR-X-nkx-5.1, are transcriptional repressors of Xanf-1 which elicits brain outgrowths, our results indicate that the function of the intact X-nkx-5.1 in cells of the anterior neural fold is much more complex than the Xanf-1 inhibition. Thus, X-nkx-5.1 might also operate as the direct transcriptional activator of some other genes essential for the forebrain development.
The long-term morphological effects described above have been analyzed only for the embryos which demonstrated the primary FLD localization within the anterior neurectoderm. However, we still could not exclude a possibility of some indirect influences of the microinjected X-nkx-5.1 and its derivatives via changing of inductive properties of the axial mesoderm. To check for this possibility, the mRNA constructs were specifically delivered to the ectoderm by injecting the embryos at the 32-cells stage into the animal blastomeres known to give rise to the ectoderm. At the beginning of gastrulation, the obtained embryos were selected for specific FLD localization within the presumptive neurectoderm and epidermis, and the specificity of ectodermal localization of the microinjected material was further confirmed by dissection after in situ hybridization under the fluorescent stereomicroscope. These embryos have displayed the same set of anterior neural plate abnormalities and alterations of Xanf-1 expression (not shown) as the embryos in the previous experiments in which no special measures have been applied to ensure the ectodermal delivery of the microinjected constructs.
2.6. Xanf-1 is the direct target of X-nkx-5.1 in the embryonic cells
To demonstrate that Xanf-1 is a direct target of X-nkx-5.1 in the embryonic cells, we have microinjected the embryos with a dexamethasone-inducible construct containing a fusion of the dominant activator version VP16-X-nkx-5.1 with the Binding Domain of Glucocorticoid Receptor (BDGR). Normally, such fusion proteins appear to be inactive in the cells due to sequestration of BDGR by the hsp90 heat-shock protein complex, (Gammill and Sive, 1997; Ermakova et al., 1999) . At the end of gastrulation, the microinjected embryos were placed for 1 hour into the 10 mg/ml cycloheximid (CHX) solution. Previously, this period of time has been established as sufficient to block the total protein synthesis by more than 90% (Gammill and Sive, 1997; our unpublished data) . Next, to release the previously synthesized protein VP16-X-nkx-5.1-BDGR from the hsp90 complex within the cells, we added dexamethasone (DEX) to the same incubation solution to the final concentration of 2 mM. Such activation of VP16-X-nkx-5.1-BDGR under the translational block conditions should affect only direct targets of this dominant-negative version of the transcription factor. After two hours of incubation with CHX and DEX, the embryos were processed for the whole-mount in situ hybridization. We have observed an expansion of the Xanf-1 expression area in the DEX-treated embryos (23 embryos in two experiments) (Fig. 4K,K 0 , arrow), as opposed to those incubated without DEX (Fig. 4 , L,L 0 ). Taken together, these results prove direct interaction of VP16-X-nkx-5.1-BDGR with the Xanf-1 promoter in living embryos.
2.7. Down-regulation of X-nkx-5.1 by the anti-sense morpholino oligonucleotides confirms its involvement in the spatial and temporal regulation of the Xanf-1 expression and formation of the epidermal ciliated cells
To further confirm the repressor role of X-nkx-5.1 in regulation of the Xanf-1 expression, we have inhibited . This results in a moderate lateral expansion of the Xanf-1 expression domain outside of the neural plate (Fig. 5A ,A 0 , arrow). Importantly, in all cases (31 embryos in 3 independent experiments) this expansion of the Xanf-1 expression never reaches far from the neural plate, despite the fact that in many embryos the MO-containing cells occupy much broader territories. This result is consistent with the expected specific effect of the X-nkx-5.1 MO, which presumably should not be able to elicit the expansion of the Xanf-1 expression beyond the limits of the endogenous X-nkx-5.1 expression territory.
To demonstrate a stage-specific regulatory role of X-nkx-5.1 in the Xanf-1 expression, we have observed the embryos microinjected with the X-nkx-5.1 MO at the stages when the Xanf-1 expression in the neural plate should be normally reduced (stages 17-18). Instead, the Xanf-1 expression in the neural plate has been prolonged (17 embryos in two experiments) (Fig. 5E-F 0 ). However, this prolongation is temporary and the Xanf-1 expression in the neural anlage of the MO-treated embryos has still ceased by the early tailbud stage (Fig. 5G-H 0 ).
In general, MO microinjections are known to result in the overall developmental delay in the embryos, and such delay might by itself cause the observed temporal prolongation of the Xanf-1 expression. To test for this possibility, we have microinjected the control MO provided by Gene-Tools at the concentrations 2 times higher than for the anti-X-nkx-5.1 MO (not shown). The control experiments show no temporal prolongation of the Xanf-1 expression, indicating the specificity of the effects generated by the anti-X-nkx-5.1 MO.
We have further tested this specificity by using the dominant repressor version of X-nkx-5.1 (EnR-X-nkx-5.1) to override the X-nkx-5.1 MO effects. The construct EnR-Xnkx-5.1 has an advantage of exerting a similar inhibitory effect on the Xanf-1 expression as the intact X-nkx-5.1, but not having the MO target site. So, its translation could not be inhibited by the X-nkx-5.1 MO. Thus, a mixture of the X-nkx-5.1 anti-sense MO and EnR-X-nkx-5.1 mRNA (1.0 mM MOC200 ng/ml of mRNA) was microinjected into the embryos. Instead of expansion of the Xanf-1 expression zone, we have observed the inhibition of the Xanf-1 expression (26 embryos in two experiments) (Fig. 5B,B 0 , see arrow), thus confirming the specificity of the X-nkx-5.1 MO effects.
The MO approach has been further utilized to better characterize the function of X-nkx-5.1 during early neural development, and to test the extended morphological effects of the X-nkx-5.1 inhibition on the forebrain development. As a result, we have observed a severe reduction of the forebrain and eye (Fig. 5I, I 0 ) on the microinjected side of embryo. Together with the data described in 2.5, this result indicates that in addition to the role in temporal and spatial restriction of the Xanf-1 expression, X-nkx-5.1 has another function in cells of the anterior neural plate, which is essential for the further forebrain development.
As the epidermal pattern of the X-nkx-5.1 expression resembles the scattered distribution of the epidermal ciliated cells precursors, we have used the MO-injected embryos to test for a possible involvement of X-nkx-5.1 in the ciliated cells differentiation. As a result, we have observed almost total reduction of expression of the ciliated cells marker, b-tubulin (Tichelaar et al., 1999a,b) , within the epidermal territories composed by the MO-containing cells (27 embryos in two experiments) (Fig. 5C,D) .
X-nkx-5.1 is essential for the normal anterior neural patterning
For more complete analysis of the X-nkx-5.1 role in the anterior neural development, we have characterized the effects of its downregulation (the MO microinjections) and overexpression (the X-nkx-5.1 microinjections) on expression of the following genetic markers: Bf-1, NCAM, Nkx-2.4, OtxK2, Pax-6, Six-3. During neurulation, the expression areas of all these markers overlap, at least partially, with that of X-nkx-5.1, which may indicate a possible involvement of X-nkx-5.1 in their regulation. Our data show that the X-nkx-5.1 overexpression results in a severe inhibition of expression of Bf-1, NCAM, Otx-2, 18, 21, 20 and 21 embryos, respectively, in 2 independent experiments) (Fig. 6B,B 0 ,E,E 0 ,H,H 0 ,K,K 0 , N,N 0 , arrows). In contrast, the Nkx-2.4 expression appears to be increased (12 embryo in 2 experiments) (Fig. 6Q,Q 0 , arrow). In a good agreement with the latter effect, the Nkx-2.4 expression is severely inhibited if the X-nkx-5.1 expression is down-regulated with the MO microinjections (14 embryos in 2 experiments) (Fig. 6R, R 0 , arrow). Expression of the other analyzed markers has been also affected in the MO microinjected embryos but to a lesser extent than in the case of X-nkx-5.1 overexpression. Thus, a comparatively strong inhibitory effect is observed only for Otx-2 expression (17 embryos in 2 experiments) (Fig. 6I,I 0 , arrow). This inhibition could be explained by an increased level of the Xanf-1 expression in the absence of X-nkx-5. shown earlier, overexpression of Xanf-1 elicits inhibition of the Otx-2 expression (Ermakova et al., 1999) . For the markers Bf-1, NCAM, Pax-6, and Six-3 (20, 18, 23 and 25 embryos, respectively, in 2 experiments) only minor changes in the expression patterns, including slight expansion or reduction of expression areas, have been observed in the MO treated embryos (Fig. 6C, 
. Taken together, these data indicate that the role of X-nkx-5.1 during early development of the anterior neural plate is not limited to the inhibitory influence on the Xanf-1 expression, but may also include transcriptional regulation of some other genes.
Discussion
3.1. The role of X-nkx-5.1 in restriction of the Xanf-1 expression Our data demonstrate the role of X-nkx-5.1 as one of transcriptional repressors responsible for the temporal and spatial restriction of the Xanf-1 expression in the anterior neural plate. First, X-nkx-5.1 is able to bind to the Xanf-1 promoter fragment both in vivo (in yeast) and in vitro (in EMSA). Second, the N-terminal part of X-nkx-5.1 contains a motif that has been previously determined as the repression domain in many other transcription factors (Smith and Jaynes, 1996) . Third, the beginning of the X-nkx-5.1 expression in the anterior neurectoderm coincides with the decrease of the Xanf-1 expression in the same region. Forth, both native X-nkx-5.1 and its dominant repressor variant, EnR-X-nkx-5.1, can inhibit expression of the endogenous Xanf-1, whereas the dominant activator version, VP16-X-nkx-5.1, is able to up-regulate the Xanf-1 expression in Xenopus embryos. Importantly, the latter effect is also observed when the hormone-inducible version, VP16-X-nkx-5.1-BDGR, is used under the conditions of total protein synthesis inhibition, thus indicating a direct interaction of X-nkx-5.1 with the Xanf-1 promoter. In addition, VP16-X-nkx-5.1 is able to elicit the same set of anatomical abnormalities as the ectopic expression of Xanf-1. Finally, suppression of translation of the X-nkx-5.1 mRNA by the anti-sense morpholino oligonucleotides results in expansion of the Xanf-1 expression zone and temporary prolongation of its expression.
At the same time, other transcription factors may also be involved in the process of inhibition of the Xanf-1 expression as indicated indirectly by some of our data. When the X-nkx-5.1 mRNA translation is inhibited by the anti-sense morpholino oligonucleotides (MO), the Xanf-1 expression in the anterior neural plate does not continue indefinitely, it still gets terminated by the end of neurulation. The MO are known to be very stable in the Xenopus embryos, and their influence can last up to the tadpole stage (Nutt et al., 2001 ). Thus, the observed termination of Xanf-1 expression cannot be attributed simply to MO degradation by the end of neurulation, and additional experiments need to be performed to identify other transcription factors responsible for this effect.
Our data show that when the dominant activator version of X-nkx-5.1 is ectopicaly expressed, the endogenous Xanf-1 expression zone expands exclusively in the anterior and lateral directions but never in the posterior one. Therefore, some unknown repressors operating in the cells located just posterior to the Xanf-1 expression domain may effectively compete with VP16-X-nkx-5.1 for the influence on the Xanf-1 promoter. The observed effect resembles, at least in general, the phenomenon of posterior prevalence described earlier for the homeobox genes of HOX complex. According to the rule of posterior prevalence, a given ectopically expressed HOX gene can regulate the expression of its genetic targets only in those cells of the body axis that are located anterior to the natural expression zone of this HOX gene (reviewed by Duboule and Morata, 1994) . In vertebrate embryos, this rule is valid for the most HOX genes expressing in the trunk region, between the level of midhindbrain boundary and the tail of embryo. Our finding demonstrates that a similar rule, though having a different genetic basis, may also be valid for the more anterior region of embryo.
Our results show that microinjections of mRNA encoding the intact X-nkx-5.1 and its dominant activator version, VP16-X-nkx-5.1, elicit development of the abnormal brain outgrowths that closely resemble the ones previously observed for the Xanf-1 mRNA microinjections (Ermakova et al., 1999) . In contrast, microinjections of both dominant repressor EnR-X-nkx-5.1 mRNA and anti-X-nkx-5.1 MO never result in the brain outgrowths, but instead lead to the brain reduction. Taken together, these data indicate a much broader role for X-nkx-5.1 during the forebrain development than just the direct inhibition of the Xanf-1 expression. Moreover, the morphological effects of the intact X-nkx-5.1 are similar to the ones elicited by its dominant activator version, suggesting that this factor might as well operate as a transcriptional activator and not only as the transcriptional repressor for Xanf-1. The activator function may be associated with potential interactions of X-nkx-5.1 with some others proteins. The in situ hybridization experiments with a panel of probes for different genetic markers support our idea about the complexity of X-nkx-5.1 roles in Xenopus development, which would be addressed in the further work.
Comparison of expression patterns of X-nkx-5.1 and its orthologs in other species
Our data show that many features of the X-nkx-5.1 expression closely resemble the expression patterns that have been previously demonstrated for its orthologs in other species, including two expression domains within the ventral part of the brain, in the ear placodes and vesicles, in the otic ganglion and in neurons within the spinal cord observed in medaka, zebrafish, chick and mouse (Adamska et al., 2000; Adamska et al., 2001 ). In addition, similarly to its zebrafish and medaka counterparts, the expression of X-nkx-5.1 is revealed in cells of the lateral line placode. This finding supports the previously published idea about the common evolution origin of the sensorial epithelium of the ear placodes and lateral line (Adamska et al., 2000; Adamska et al., 2001) .
A novel feature of the X-nkx-5.1 elucidated in our work is a very early start of its expression. The transcript is detected in scattered cells of the epidermal inner layer starting from the early gastrula, and in cells of the anterior neural fold at the beginning of midneurula stage. This early expression of X-nkx-5.1 during Xenopus development has been detected first by cloning of the X-nkx-5.1 cDNA from the late gastrula cDNA library, and second by RT-PCR and in situ hybridisation. No such early expression at the homologous stages has been previously reported for the X-nkx-5.1 orthologs in other vertebrates. This heterochrony could be explained by some specific features of the frog embryogenesis, in particular, by development of the epidermal ciliated cells. Alternatively, the early expression of the X-nkx-5.1 counterparts in other species might be too weak to get detected by RNA blotting or in situ hybridisation. Therefore, additional efforts are necessary to establish that the expression of the X-nkx-5.1 orthologs starts not earlier than the end of neurulation, as previously reported.
The X-nkx-5.1 expression pattern observed in the embryonic epidermis is very similar to the patterns of genes associated with the precursors of ciliated epidermal cells, including X-Delta-1 (Deblandre et al., 1999) , and b-tubulin,which is widely used as the marker of ciliated cells (Tichelaar et al., 1999a,b; Okada et al., 2003) . The involvement of the X-nkx-5.1 in the process of the epidermal ciliated cells differentiation is also confirmed by the observed inhibition of the b-tubulin expression in embryos microinjected with the X-nkx-5.1 anti-sense MO.
Differentiation of the ciliated cells is considered to be regulated by the Delta-Notch signalling pathway in all model system investigated thus far, including the chicken inner ear and Xenopus epidermis (Adam et al., 1998; Deblandre et al., 1999) . The characteristic scattered pattern of the X-Delta-1 expression is the result of lateral inhibition. This process involves an increase of the level of the membrane ligand Delta-1 in a given cell which leads to activation of the Delta-1 transmembrane receptor Notch in the adjacent cells. In turn, activation of the Notch signalling in these cells elicits down-regulation of Delta-1, and a set of other transcription factors responsible for progression of the ciliated cells differentiation program (see for review Artavanis-Tsakonas et al., 1995) . We assume that X-nkx-5.1 is expressed in the embryonic epidermis in a fashion very similar to the X-Delta-1 expression (described in Deblandre et al., 1999) , in scattered single cells surrounded by cells that don't express this transcription factor. Our data show that down-regulation of X-nkx-5.1 elicits inhibition of the ciliated cells differentiation. Thus, we hypothesize that the expression of this gene may be an essential factor for some early steps of the ciliated cells differentiation.
Interestingly, in some other cases, nkx-5.1 can also control the ciliated cells differentiation in concert with the Notch-Delta pathway. Thus, during differentiation of the ciliated sensorial cells in the developing otic vesicles in mouse and chick embryos, nkx-5.1 starts to be expressed for the first time at the end of neurulation in the anterior neurogenic part of the placode, i.e. in the same place and approximately at the same time as Delta-1 (Rinkwitz- Brandt et al., 1995; Adam et al., 1998; Herbrand et al., 1998; Lewis et al., 1998) . These data indicate the tight coupling of Nkx-5.1 and X-Delta-1 during differentiation of the ciliated cells. In turn, this suggests that the ciliated cells in the otic vesicle, lateral line and epidermis might be derived from a common ancestory line of sensorial cells in the process of evolution.
Materials and methods
Yeast one-hybrid screening
A construct containing the target 34-bp element from the Xanf-1 promoter along with the flanking restriction sites was prepared using the following oligomers: 5 0 -aattcatgtcgacTGCTAATTACACACCAAACAAA-TAAACAATTAAC and 5 0 -tcGAGTTAATTGTTTATTTGTTTGGTGTGTAATTAGCAgtcgacatg (here and below the target sequence is in capital letters).
This construct was sequentially inserted in three copies into pHisi and pLacZi reporter vectors (Clontech Laboratories) upstream of the reporters (HIS3 and LacZ, respectively) using EcoRI, Sal I and XhoI restriction sites. The obtained pHisi and pLacZi reporter plasmids were integrated into the genome of YM4271 yeast strain (Matchmaker One-Hybrid System, Clontech) at HIS3 and URA3 loci, respectively. The obtained target-reporter strain in YM 4271 background carried deletions of the wild-type genes required for activation of the Gal1 promoter. However, we needed to use a cDNA library from the LexA yeast two-hybrid system that was created using the Gal1 promoter-driven expression vector. Thus, to restore the ability to activate the Gal 1 promoter, we mated the obtained target-reporter strain with the Egy48 strain (Ade K and Tyr K auxotrophic) from LexA twohybrid system. The obtained diploid yeast strain could grow on the Ade/-His/-Tyr/-Ura selective medium due to a leaky HIS3 expression, but was completely suppressed on this medium in the presence of 80 mM 3-aminothriasol (3-AT). This strain was transformed with the Matchmaker LexA cDNA library prepared from Xenopus laevis embryo stage 12 in pB42 AD cloning vector (Clontech Laboratories). Transformants were plated on the -Ade/-His/-Trp/-Tyr/-Ura selective medium supplemented with 80 mM 3-AT. These conditions only supported growth of colonies in which HIS3 reporter gene was activated by transcription factors binding to the 34-bp target sequence. To eliminate false positives, we also tested the lacZ reporter gene expression in the obtained colonies that were grown on the Lac selective medium by using the b-galactosidase filter assay. The selected yeast colonies were used to isolate plasmids containing Xenopus cDNA inserts. The plasmids were re-transformed into E.coli, and then the cDNA inserts were amplified by PCR and analyzed using HaeIII restrictase digestion to select for unique clones. Finally, the selected clones were tested by re-transformation into the initial one-hybrid yeast reporter strain, sequenced and analyzed using BLAST database searches.
Gel-shift analysis (EMSA)
Oocytes were microinjected with mRNA of EGFP and X-nkx-5.1 (10 ng/oocyte) and incubated 48 hours in OR-2 solution. Then they were disrupted by pipetting in the EMSA buffer (100 mM KCl, 0.25 mM EDTA, 0.2 mM EGTA, 20% glycerol, 100 mg/ml BSA, 20 mM HEPES pH 7.9, plus the protease inhibitor cocktail containing chymostatine, leupeptine pepstatin and PMSF each at final concentration 10 mg/ml) in the volume of 10 mcl/oocytes, and centrifuged at 4 8C and 12,000 rpm for 5 min. Finally, 10 ml of the oocyte extract were diluted ten times by EMSA buffer, mixed with 2 mg of Poly(dI-dC) and incubated at 4 8C for 15 min. The following double stranded oligonucleotides were used for EMSA: for the normal 14-bp element, 5 0 -tctgtcccaTGCTAATTACACAC; for the normal 22 bp element, 5 0 -tctgcatgtcgaCAAACAAATAAACAATTAACTCga; and for a mutant 22 bp element, 5 0 -tctgcatgtcgaCAAACAAATAAACAAGTAACTCga. In total, 50 pmol of each oligonucleotide were P 32-endlabeled using T4 polynucleotide kinase, added to the oocyte extracts (15,000 cpm per each reaction) and incubated at 4 8C for 40 min. The final volume was adjusted to 15 ml by the EMSA buffer. The reaction products were immediately loaded on a 6% polyacrylamide gel containing 0.5x TBE and run for 50-60 min at a constant current (100 mA).
Preparation of DNA constructs and mRNA for microinjections
The full-length coding sequence of X-nkx-5.1 was obtained by RT-PCR from a total RNA sample extracted from the head of embryo at stage 42 using the following pair of primers:
forward: 5 0 -AGAACCGGTCTGACACCCTCCATCTG reverse: 5 0 -CTACTCGAGTCACACTGGCCTGAGCA AAGGTACTGA.
The obtained PCR fragment was digested with Age I and Xho I and cloned into pSP-EGFP plasmid instead of EGFP (described in Ermakova et al., 1999) to create a vector for synthesis of the intact X-nkx-5.1 mRNA.
The fusions of X-nkx-5.1 with the activator domain from herpes virus VP16 protein (VP16) or the repressor domain from Drosophila engrailed (EnR) (Jaynes and O'Farrel 1991) , were prepared using a fragment of X-nkx-5.1 cDNA coding for the DNA binding domain. This fragment was cloned using the following pair of primers:
forward: 5 0 -ACAGGATCCTGGTGGTATTCTTATA-CCTT reverse: 5 0 -CTAAAGCTTCACACTGGCCTGAGCA-AAGGTACTGA The amplified fragment was digested with BamHI and HindIII and cloned instead the Xanf-1-BDGR cassette in the two previously described plasmids, pSP-EnR-Xanf-1-BDGR and pSP-VP16-Xanf-1-BDGR, respectively (Ermakova et al., 1999) .
The dexamethasone-inducible version of VP16-X-nkx-5.1 was prepared from the X-nkx-5.1 fragment amplified by PCR with the following pair of primers:
forward: 5 0 -ACAGGATCCTGGTGGTATTCTTAT-ACCTT reverse: 5 0 -CTACTCGAGACACTGGCCTGAGCAAA-GGTACTGA It was digested with BamHI and XhoI and utilized to replace Xanf-1 in the previously described plasmid pSP-VP16-Xanf-1-BDGR (Ermakova et al., 1999) .
Microinjections and manipulations with embryos
Xenopus eggs were fertilized in vitro and de-jellied in 2% cysteine at pH 7.8. Injections were performed at 32-cell stages in 0.1!MMR, 4% Ficoll and, 2 hours later, the injected eggs were transferred to 0.1!MMR for further incubation. Normal fate maps of individual blastomeres of 32-cell stage embryos were used from Bauer et al., 1994. Injected embryos were staged according to Nieuwkoop and Faber (1967) . Vitellin membranes were removed at the appropriate stage manually in 0.5!MMR. Brains of the 5 days tadpoles were excised by forceps in 1!MMR solution.
Design and microinjections of the morpholino oligonucleotides (MO)
The morpholino oligonucleotide (MO) 5 0 -CTCCTG-TCCTGTCTCGGGCATGATA was designed based on BLAST analysis of the Xenopus laevis NR and EST databases, as recommended by the manufacturer (Gene Tools, LLC). From 2 to 3 nl of the 1 mM water solution of this MO were microinjected into animal-dorsal blastomeres of the Xenopus laevis embryos at stages 2-8 blastomeres.
Standard control MO 5 0 -CCTCTTACCTCAGTTA-CAATTTATA was provided by the manufacturer. It was microinjected in the Xenopus embryos as 3 nl of 1 or 2 mM water solutions.
RT-PCR assay and whole-mount in situ hybridization
RT-PCR analysis of the X-nkx-5.1 expression was done as described in Zaraisky et al., 1992 using the following pair of primers: 5 0 -AGAACCGGTCTGACACCCTCCATCTG 5 0 -CCGGGATCCAGCAGAAGGCTCTTGTCTGG As an internal control, the EF-1a expression was monitored in the same samples with the primers:
The analysis was repeated using two independently isolated series of the total RNA samples.
The RNA probe for whole-mount in situ hybridization was prepared by PCR from yeast plasmid containing a part of the coding sequence of X-nkx-5.1 with the following pair of primers: 5 0 -CCAGCCTCTTGCTGAGTGGAGATG 5 0 -TAATACGACTCACTATAGGGCGAAGAAGTC-CAAAGC, followed by the T7 RNA polymerase transcription. The whole-mount in situ hybridization was performed as described by Harland (1991) with minor variations.
